Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies

Therapeutic monoclonal antibodies (mAbs), which are developed to treat many pathologies, including cancer, autoimmune and infectious diseases, are one of the fastest growing classes of medicinal products. Given the large number of mAbs in the pipeline and continued interest from pharmaceutical compa...

Full description

Bibliographic Details
Main Authors: V. V. Smirnov, O. A. Petukhova, A. V. Filatov, D. A. Kudlay, M. R. Khaitov
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2023-06-01
Series:Биопрепараты: Профилактика, диагностика, лечение
Subjects:
Online Access:https://www.biopreparations.ru/jour/article/view/434
_version_ 1797244480024215552
author V. V. Smirnov
O. A. Petukhova
A. V. Filatov
D. A. Kudlay
M. R. Khaitov
author_facet V. V. Smirnov
O. A. Petukhova
A. V. Filatov
D. A. Kudlay
M. R. Khaitov
author_sort V. V. Smirnov
collection DOAJ
description Therapeutic monoclonal antibodies (mAbs), which are developed to treat many pathologies, including cancer, autoimmune and infectious diseases, are one of the fastest growing classes of medicinal products. Given the large number of mAbs in the pipeline and continued interest from pharmaceutical companies, the mAb market is expected to continue to grow in the coming years. To maximise both the therapeutic benefit and the safety of medicinal products in this class, it is essential that their pharmacological properties be carefully characterised and understood.The aim of the study was to analyse literature data on approaches to studying the pharmacokinetics of mAbs. This review presents data on the main physicochemical and pharmacological properties of mAbs and compares them with small molecules. The article describes the influence of various factors on mAb pharmacokinetics.For example, such factors include the method of administration, hydrophilicity, and charge of the mAb, individual characteristics of the patient (body weight, plasma albumin levels, genetic characteristics, etc.), and concurrent administration of other medicinal products. The authors evaluated the role of intra- and inter-individual variability of pharmacokinetic parameters. The rapid development of this group of medicinal products and the emergence of new promising molecules are indicative of the need to study the pharmacokinetics and pharmacodynamics of mAbs in detail and to maximise both the therapeutic benefit and the safety of the medicinal products in this class.
first_indexed 2024-03-08T21:42:58Z
format Article
id doaj.art-57fbb0dd5c1b4995ba124095c6852e6c
institution Directory Open Access Journal
issn 2221-996X
2619-1156
language Russian
last_indexed 2024-04-24T19:11:40Z
publishDate 2023-06-01
publisher Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
record_format Article
series Биопрепараты: Профилактика, диагностика, лечение
spelling doaj.art-57fbb0dd5c1b4995ba124095c6852e6c2024-03-26T09:10:54ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562023-06-0123217318010.30895/2221-996X-2023-23-2-173-180319Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodiesV. V. Smirnov0O. A. Petukhova1A. V. Filatov2D. A. Kudlay3M. R. Khaitov4NRC Institute of Immunology of the FMBA of Russia; I. M. Sechenov First Moscow State Medical University (Sechenov University)NRC Institute of Immunology of the FMBA of RussiaNRC Institute of Immunology of the FMBA of RussiaNRC Institute of Immunology of the FMBA of Russia; I. M. Sechenov First Moscow State Medical University (Sechenov University)NRC Institute of Immunology of the FMBA of RussiaTherapeutic monoclonal antibodies (mAbs), which are developed to treat many pathologies, including cancer, autoimmune and infectious diseases, are one of the fastest growing classes of medicinal products. Given the large number of mAbs in the pipeline and continued interest from pharmaceutical companies, the mAb market is expected to continue to grow in the coming years. To maximise both the therapeutic benefit and the safety of medicinal products in this class, it is essential that their pharmacological properties be carefully characterised and understood.The aim of the study was to analyse literature data on approaches to studying the pharmacokinetics of mAbs. This review presents data on the main physicochemical and pharmacological properties of mAbs and compares them with small molecules. The article describes the influence of various factors on mAb pharmacokinetics.For example, such factors include the method of administration, hydrophilicity, and charge of the mAb, individual characteristics of the patient (body weight, plasma albumin levels, genetic characteristics, etc.), and concurrent administration of other medicinal products. The authors evaluated the role of intra- and inter-individual variability of pharmacokinetic parameters. The rapid development of this group of medicinal products and the emergence of new promising molecules are indicative of the need to study the pharmacokinetics and pharmacodynamics of mAbs in detail and to maximise both the therapeutic benefit and the safety of the medicinal products in this class.https://www.biopreparations.ru/jour/article/view/434monoclonal antibodiesmabspharmacokinetic parametersbiosimilar medicinal productsmolecular targetbiotechnology
spellingShingle V. V. Smirnov
O. A. Petukhova
A. V. Filatov
D. A. Kudlay
M. R. Khaitov
Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
Биопрепараты: Профилактика, диагностика, лечение
monoclonal antibodies
mabs
pharmacokinetic parameters
biosimilar medicinal products
molecular target
biotechnology
title Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
title_full Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
title_fullStr Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
title_full_unstemmed Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
title_short Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
title_sort studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
topic monoclonal antibodies
mabs
pharmacokinetic parameters
biosimilar medicinal products
molecular target
biotechnology
url https://www.biopreparations.ru/jour/article/view/434
work_keys_str_mv AT vvsmirnov studyingthepharmacokineticsofbiotechnologicalmedicinalproductsontheexampleofmonoclonalantibodies
AT oapetukhova studyingthepharmacokineticsofbiotechnologicalmedicinalproductsontheexampleofmonoclonalantibodies
AT avfilatov studyingthepharmacokineticsofbiotechnologicalmedicinalproductsontheexampleofmonoclonalantibodies
AT dakudlay studyingthepharmacokineticsofbiotechnologicalmedicinalproductsontheexampleofmonoclonalantibodies
AT mrkhaitov studyingthepharmacokineticsofbiotechnologicalmedicinalproductsontheexampleofmonoclonalantibodies